CompletedNot Applicable

Driving Reduced AIDS-associated Meningo-encephalitis Mortality

Cameroon, Malawi, Tanzania495 participantsStarted 2016-04-23

Plain-language summary

The DREAMM project is investigating whether the DREAMM interventions (1) Health system strengthening, 2) Co-designed education programs tailored to frontline healthcare workers, 3) Implementation of a diagnostic and treatment algorithm and, 4) Communities of practice in infectious diseases and laboratory capacity building) when combined reduce two week all-cause mortality of HIV-associated meningo-encephalitis in African LMICs.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Consecutive patients \> 18 years with 1st episode of suspected meningo- encephalitis
✓. Known to be HIV positive or willing to undertake an HIV test
✓. Willing to agree to participate in the study

Exclusion criteria

✕. Patients presenting with suspected relapse of HIV-associated meningo-encephalitis
✕. HIV negative patients
✕. Pregnant or lactating patients
✕. Patients presenting with a known diagnosis of primary CNS Lymphoma or cerebral malaria
✕. COVID-19 infected patients

What they're measuring

2-week all-cause mortality

Timeframe: 2 weeks from enrolment

Trial details

NCT IDNCT03226379

SponsorSt George's, University of London

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2021-04

View on ClinicalTrials.gov More AIDS-Related Opportunistic Infections trials